News Releases
Steele Children's Research Center's Novel Cancer Vaccine
By: Darci Slaten, AHSC Office of Public Affairs
A novel therapeutic cancer vaccine developed by a research team at The University of Arizona Steele Children’s Research Center is advancing toward use in human clinical trials.
Dr. Emmanuel Katsanis, professor of pediatrics and a BIO5 member at the UA, and his research team developed the vaccine Chaperone Rich Cell Lysate, or CRCL, which utilizes proteins known as chaperone proteins. These special proteins are found inside cancer cells and are associated with the protein antigens unique to the individual’s cancer.
By: Darci Slaten, AHSC Office of Public Affairs
A novel therapeutic cancer vaccine developed by a research team at The University of Arizona Steele Children’s Research Center is advancing toward use in human clinical trials.
Dr. Emmanuel Katsanis, professor of pediatrics and a BIO5 member at the UA, and his research team developed the vaccine Chaperone Rich Cell Lysate, or CRCL, which utilizes proteins known as chaperone proteins. These special proteins are found inside cancer cells and are associated with the protein antigens unique to the individual’s cancer.
